Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,047,682
  • Shares Outstanding, K 79,430
  • Annual Sales, $ 175,110 K
  • Annual Income, $ -221,250 K
  • EBIT $ -160 M
  • EBITDA $ -156 M
  • 60-Month Beta 0.61
  • Price/Sales 5.72
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 102.02% (-9.82%)
  • Historical Volatility 50.39%
  • IV Percentile 19%
  • IV Rank 10.63%
  • IV High 461.32% on 05/07/25
  • IV Low 59.29% on 08/20/25
  • Expected Move (DTE 25) 2.58 (19.06%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 158
  • Volume Avg (30-Day) 115
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 23,755
  • Open Int (30-Day) 23,072
  • Expected Range 10.98 to 16.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.27
  • Number of Estimates 1
  • High Estimate $-0.27
  • Low Estimate $-0.27
  • Prior Year $-1.15
  • Growth Rate Est. (year over year) +76.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +35.60%
on 03/24/26
13.66 -0.77%
on 04/20/26
+2.35 (+20.96%)
since 03/20/26
3-Month
10.00 +35.60%
on 03/24/26
14.68 -7.60%
on 01/22/26
-0.59 (-4.17%)
since 01/20/26
52-Week
2.21 +513.57%
on 05/08/25
18.31 -25.94%
on 12/23/25
+9.53 (+236.48%)
since 04/17/25

Most Recent Stories

More News
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA ® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 13.50 (+2.35%)
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04,...

PHAT : 13.50 (+2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 14.02
2nd Resistance Point 13.65
1st Resistance Point 13.42
Last Price 13.50
1st Support Level 12.81
2nd Support Level 12.44
3rd Support Level 12.21

See More

52-Week High 18.31
Last Price 13.50
Fibonacci 61.8% 12.16
Fibonacci 50% 10.26
Fibonacci 38.2% 8.36
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.